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ABSTRACT 
 
INTRODUCTION:  The incidence of symptomatic venous thromboembolism (VTE), 
which comprises deep venous thrombosis (DVT) and pulmonary embolism (PE) at a 
population-based level remains unknown in patients undergoing major urologic surgery. 
Our aim was to determine the incidence of VTE in major urologic surgery, identify 
patients who are at high risk for developing these events, and to examine whether the use 
of pharmacologic thromboprophylaxis is associated with a reduction in the incidence of 
VTE in major urologic surgery.  
 
METHODS: We captured all adult patients who underwent major urologic surgery 
between January 2005 and December 2010 based on 1CD-9-CM codes from the 
Perspective Database (Premier, Inc, Charlotte, NC), a nationally representative dataset 
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capturing 25% of US hospital discharges. Major urologic surgery was defined as a radical 
prostatectomy, radical cystectomy, radical nephrectomy or partial nephrectomy. We used 
ICD-9-CM codes to identify VTE and major bleeding after major urologic surgery within 
90 days after the procedure and hospital billing descriptions to identify if patients had 
received pharmacologic thromboprophylaxis beginning the day of surgery. Univariate 
and multivariate analyses were performed using STATA 12 (StataCorp LP, 
CollegeStation, Texas) after adjusting for sample weights.  
 
RESULTS: Among our cohort with a weighted sample size of 709,294 patients, the 
highest rate of VTE was associated with radical cystectomy (5.33%), followed by radical 
nephrectomy (1.52%), partial nephrectomy (0.99%), and radical prostatectomy 
(0.60%).  Independent risk factors for post-operative VTE included advanced age, men, 
minimally invasive surgery, and surgery performed at a teaching hospital.  We did not 
find a clear association with pharmacologic thromboprophylaxis use and a decreased 
odds of developing a VTE, except in patients undergoing radical prostatectomy surgery.  
Also, only in radical nephrectomy and radical prostatectomy surgery was the use of 
pharmacologic thromboprophylaxis associated with an increased odds of developing a 
major bleeding episode.  
 
CONCLUSION:  Post-operative VTE is relatively uncommon following major urologic 
surgery.  Radical cystectomy had the highest incidence of post-operative VTE potentially 
due to the patient population, which is older and with more comorbidities.  It remains 
 vi
unclear whether the use of pharmacologic thromboprophylaxis is warranted in patients 
undergoing most major urologic procedures and further research should be directed at 
elucidating the benefits as well as the costs of this prophylaxis method in this patient 
population.     
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INTRODUCTION 
 
Venous thromboembolism (VTE), which comprises deep venous thrombosis (DVT) and 
pulmonary embolism (PE), represents a major burden on the US healthcare system.  It 
has been estimated that there is annual incidence of 900,000 clinically evident cases 
resulting in 300,000 deaths1 and VTE represent the second most common cause of 
medical complication, excessive length of hospital stay and third most common cause of 
excessive mortality2.  Patients undergoing cancer surgery are at one of the highest risks 
for developing VTE and it is associated with a twenty-fold increase in the odds of 
developing a VTE3.  
Starting in 1986, in an effort to reduce the incident of VTE in surgical procedures 
and improve patient safety, the American College of Chest Physicians (ACCP) set forth a 
series of perioperative VTE prophylaxis guidelines for patients undergoing surgery.   
Patients undergoing radical prostatectomy, radical cystectomy, radical nephrectomy and 
partial nephrectomy are classified as having a moderate to high risk of developing a VTE 
due to the association of classic risk factors like pelvic surgery, advanced age and cancer 
status, with an estimated VTE risk of 15-40% without thromboprophylaxis4. For these 
major procedures, the ACCP recommends a combination of graduated compression 
stockings (GCS), Intermittent Pneumatic Compression (IPC) and the use of 
pharmacologic thromboprophylaxis in the form of injectable low dose unfractionated 
heparin (LDUH) or low molecular weight heparins (LMWH).     
The thromboprophylaxis recommendations for major urologic surgery have been 
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primarily extrapolated from studies in general and gynecology surgery, due to the paucity 
of studies done in urology4. The American Urologic Association (AUA) captures this 
sentiment in their most recently published guidelines where they assert that there is 
“insufficient outcomes data to support a formal meta-analysis and an evidence-based 
guideline on the prevention of DVT during urological surgery.5”  In the absence of high-
level studies, the use of pharmacologic thromboprophylaxis in major urologic procedures 
remains controversial due to the perception that patients undergoing these procedures 
carry a different postoperative VTE risk profile from other pelvic surgeries due to 
differences in patient positioning, time to ambulation, and use of minimally invasive 
technologies and that the use of these drugs may pose a significant bleeding risk to 
patients undergoing these procedures6-8.  Therefore, we performed a population-based 
analysis to define the frequency of symptomatic VTE and major bleeding following 
major urologic surgery, identify predisposing risk factors for these events, and to examine 
whether the use of pharmacologic thromboprophylaxis was associated with a lower 
incidence of VTE.  
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METHODS 
 
Data  
A retrospective data analysis was performed using the Perspective Database 
(Premier, Inc, Charlotte, NC), a nationally represented dataset capturing 25% of hospital 
discharges and inpatient billing records nationwide from over 600 hospitals.  The 
database meets the standards set forth by the Health Insurance Portability and 
Accountability Act (HIPPA) and is routinely used to evaluate health outcomes, 
epidemiologic trends, hospital drug utilization trends, and cost-effectiveness analysis.  
Patient billing data, primary and secondary diagnoses and other important medical 
information is gathered from linked, de-identified files.  Each patient encounter is 
identified by a unique patient identifier key and multiple patient visits can be tracked 
through a medical record number, permitting longitudinal data analyses.  Since our 
analysis utilizes data from de-identified patient records and does not require use of 
protected health information, institutional review board (IRB) approval was unnecessary.  
 
Study Cohort 
We captured patients at least 18 years of age who underwent major urologic surgery as a 
primary diagnosis between 2005 and 2010 based on the Internal Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).  Major urologic surgery 
was defined as partial nephrectomy (ICD-9-CM: 55.4), radical nephrectomy (ICD-9-CM: 
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55.51), radical cystectomy (ICD-9-CM: 57.71) or radical prostatectomy (ICD-9-CM: 
60.5).  Patients were followed for approximately 90 days after the date of surgery, 
because the risk of developing a VTE remains elevated for up to 3 months post-
operatively.  Patients were tracked during this time period or until inhopsital death to see 
if they developed a VTE or had a major bleeding episode.  In accordance with the 
recommendations set forth in the ACCP VTE Prophylaxis Guidelines4, we defined 
pharmacologic thromboprophylaxis as receiving injectable subcutaneous heparin, 
enoxaparin, fondaparinux or dalteparin on the day of major urologic surgery based on 
patient specific hospital billing descriptions.  
 We also used hospital billing descriptions to identify if a patient’s major urologic 
procedure was performed using an open, laparoscopic or robotic approach.  We 
considered patients to have undergone a minimally invasive procedure if they had either a 
laparoscopic or robotic procedure performed.  
 To measure the illness severity of each patient, we used the Charlson Comorbidity 
Score (CCS)9.  The CCS is a measure of a patient’s illness and predicts the ten-year 
mortality for the patient.  This value is generated from a weighted sum of a patient’s 
various comorbid conditions.  Each comorbid condition is assigned a value of 1, 2, 3, or 6 
and the values are summed to arrive at a patient’s CCS.  In order to calculate the score, 
baseline data was collected from previous inpatients visits up to one year before the day 
of surgery. 
Explanatory variables were assessed as both continuous and categorical variables.  
Specifically, hospital size was based on the number of beds and was broken up into 
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quartiles.  Length of hospital stay was based on the number of days a patient spent in the 
hospital and was dichotomized based on whether a patient spent two days or less in the 
hospital or greater than two days, except for patients undergoing radical cystectomy 
surgery, due to their excessive hospital stays and we therefore treated length of stay for 
these patients as a continuous variable.  Age was categorized every ten years, except for 
patients less than 40 and patients greater than 80.  
 
 
Outcomes Measured 
We identified if patients had a symptomatic VTE or major bleeding episode based on 
ICD-9-CM codes.  Specifically, patients within our 90 day study period who had an ICD-
9-CM code of 451.11, 451.19, 451.2, 451.81, 451.9, 453.40, 453.41, 453.42, 453.89, 
453.9, 459.10, 459.10, 459.11, 459.12, 459.13, 459.19 were considered to have a 
diagnosis of symptomatic deep venous thrombosis, while patients who had an ICD-9-CM 
code of 415.11, 415.12, 415.13 or 415.19 were considered to have a diagnosis of a 
pulmonary embolism.  Collectively, if a patient was diagnosed with any of the ICD-9-
CM codes previously mentioned during our study period we considered them to have had 
a symptomatic VTE.  If a patient was diagnosed with an ICD-9-CM code during the 
study period of 568.81, 430, 431, 432.0, 432.1, 432.9, 998.11, 246.3, 287.8, 287.9, 286.5, 
459.0, 530.82, 569.3, 578.0, 578.1, 578.9, 596.7, 599.70, 719.10-19, 784.7, 784.8, 
786.30, 786.39, 958.2, or 997.02 we considered the patient to have undergone a major 
bleeding episode.   
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Statistical Analyses:   
Continuous variables were described using either mean ± S.D. or median value plus 
interquartile range and categorical variables were described using frequencies and 
proportions.  Statistical differences were obtained by performing a univariate analysis on 
both continous and categoical variables.  Multivariate logistic regression models were 
built to assess the effect of pharmacologic thromboprophylaxis on the incidence of VTE 
and major bleeding episodes.  We designated a p-value of less than 0.05 to be statistically 
significant.  Data management was performed using SAS version 9.3 (SAS Institute, 
Cary, NC) and all statistical analyses were performed using STATA SE 12 (StataCorp 
LP, CollegeStation, Texas).  All analyses adjusted for sample weights to yield a 
nationally representative assessment.  
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RESULTS 
 
Study Cohort: 
A total of 100,480 patients met the study inclusion criteria, with a weighted sample size 
of 709,294 patients.  By surgery type, our weighted sample contained 58,035 patients 
who underwent a partial nephrectomy, 237,118 patients who underwent a radical 
nephrectomy, 37,678 patients who underwent a radical cystectomy, and 376,463 patients 
who underwent a radical prostatectomy.   
The baseline characteristics of the patient populations we studied are listed in 
Table 1.  Patients undergoing radical cystectomy were the oldest with a median age of 70, 
were mostly men (83.7%), had the most comorbid conditions with an average CCS of 
0.65 and spent the most days in the hospital (9).  Patients who underwent a radical 
prostatectomy tended to be younger, with a median of age of 62, had the fewest comorbid 
conditions with a mean CCS of 0.25, had the shortest hospital stays (2) and underwent 
minimally invasive surgery 39.6% of the time.   Patients undergoing partial and radical 
nephrectomy surgery had similar patient and hospital characteristics.  Patients undergoing 
a partial nephrectomy had a median age of 60, had a CCS of 0.46 and spent a median of 4 
days in the hospital, while patients undergoing radical nephrectomy surgery had a median 
age of 61, had a CCS of 0.50, and spent a median time of 4 days in the hospital.  Patients 
undergoing radical nephrectomy surgery underwent minimally invasive surgery 43.5% of 
the time, while patients undergoing partial nephrectomy surgery only underwent 
minimally invasive surgery 29.4% of the time.  The majority of major urologic 
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procedures were performed at non-teaching hospitals: radical prostatectomy was most 
common (70.6%) while partial nephrectomy was least common (60.6%).  
 
Overall Incidence of Symptomatic VTE and Major Bleeding in Major Urologic Surgery: 
We found the overall incidence of symptomatic VTE and major bleeding to be relatively 
low among the patients in our study population (Table 2).  Symptomatic VTE occurred at 
rates of 1.0%, 1.5%, 5.3%, and 0.6% while major bleeding occurred at rates of 4.2%, 
5.4%, 8.2%, and 1.8% for partial nephrectomy, radical nephrectomy, radical cystectomy 
and radical prostatectomy, respectively. 
 
Partial Nephrectomy 
Among patients undergoing partial nephrectomy surgery, the relative odds of developing 
a VTE differed by patient and surgical characteristics (Table 3A.1). Increased length of 
stay was significantly associated with the development of a symptomatic VTE.  We 
found that patients who stayed longer than two days in the hospital had an over 13-fold 
greater odds of developing a VTE than those who stayed two days or less (OR: 13.84; 
p<0.001).  Advanced age and poor health were also associated with the development of 
VTE.  Patients between 60 and 69 years of age had an over 7-fold increased odds for a 
VTE (versus patients <40 years; OR: 7.72; p<0.001) while patient in poor health (CCS 7 
to 10) had a nearly 4-fold greater odds of developing a VTE (versus CCS 0; OR: 3.47; 
p<0.001).  We also found that developing a symptomatic VTE was associated with 
minimally invasive surgery (versus open surgery; OR: 1.82; p<0.001), male gender (OR: 
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1.52; p<0.001), and surgery at a teaching hospital (versus non-teaching; OR: 1.3; 
p<0.001).  
 The strongest independent predictor for major bleeding associated with partial 
nephrectomy was health status (Table 3B.1).  Compared to healthy patients, those with a 
CCS between 7 and 10 had a 5-fold increased odds of major bleeding (versus CCS 0; OR: 
5.36; p<0.001).  Major bleeding was also associated with advanced age, male gender 
(OR: 1.22; p<0.001), and surgery at a teaching hospital (versus non-teaching; OR: 1.20; 
p<0.001)  
 
Radical Nephrectomy 
Among patients undergoing radical nephrectomy surgery, we noted the odds of 
developing a VTE varied across different clinical characteristics (Table 3A.2). The 
strongest independent risk factor for the development of VTE was increased length of 
stay.  We found that patients who stayed longer than two days in the hospital had an over 
5-fold greater odds of developing a VTE than those who stayed two days or less (OR: 
5.02; p<0.001).  Advanced age and poor health were also associated with the 
development of VTE.  There was an approximately 3-fold increased odds for developing 
a VTE among patients greater than 80 years of age (versus patients <40 years; OR: 3.20; 
p<0.001) and for patients in poor health (CCS 7 to 10) (versus CCS 0; OR: 3.07; 
p<0.001).  We also found that developing a symptomatic VTE was associated with open 
surgery (versus minimally invasive; OR: 1.68; p<0.001), male gender (OR: 1.29; 
p<0.001), and surgery at a teaching hospital (versus non-teaching; OR: 1.10; p<0.001).  
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 Health status was the strongest independent predictor for major bleeding 
associated with radical nephrectomy (Table 3B.2).  Compared to healthy patients, those 
with a CCS between 7 and 10 had a 4-fold increased odds of major bleeding  (versus 
CCS 0; OR: 4.10; p<0.001).  Major bleeding was also associated with advanced age, 
male gender (OR: 1.23; p<0.001), open surgery (versus minimally invasive; OR: 1.42; 
p<0.001) and surgery at a teaching hospital (versus non-teaching; OR: 1.14; p=0.002) 
 
Radical Cystectomy 
Among patients undergoing radical cystectomy surgery, each additional day a patient 
stayed in the hospital increased the odds of having a VTE by 5% (OR: 1.05; p<0.001).  
Our analysis revealed that the development of a symptomatic VTE was associated with 
advanced age and poor health.  Patients between 70 and 79 years of age had an over 4-
fold increased odds for a VTE (versus patients <40 years; OR: 4.19; p=0.0075) while 
patient in poor health (CCS 7 to 10) had an over 2-fold greater odds of developing a VTE 
(versus CCS 0; OR: 2.25; p=0.005).  We also found that developing a symptomatic VTE 
was associated with minimally invasive surgery (versus open; OR: 1.23; p=0.001) and 
surgery at a rural hospital (versus urban; OR: 1.40; p=0.003).  We observed no difference 
between gender and the odds of having a VTE.  
In our study cohort, health status was the strongest independent predictor for 
major bleeding associated with radical cystectomy (Table 3B.3).  Compared to healthy 
patients, those with a CCS between 4 and 6 had a 3-fold increased odds of major bleeding 
(versus CCS 0; OR: 3.01; p<0.001).  Major bleeding was also associated with surgery at 
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non-teaching hospital (versus teaching; OR: 1.14; p=0.005).  We observed no difference 
in the odds of having a major bleeding episode between different age groups, gender and 
surgical approach.   
 
Radical Prostatectomy 
Independent predictors for developing VTE are listed in Table 3A.4.  The greatest factor 
for the development of VTE was increased length of stay.  Patients who were inpatients 
for longer than two days had nearly a 5-fold greater odds of developing a VTE (versus 
length of stay ≤2 days; OR: 4.83; p<0.001).  Advanced age and poor health were also 
associated with the development of VTE.  Patients between 70 and 79 years of age had a 
63% increased odds for a VTE (versus patients between 40 and 49 years; OR: 1.63; 
p<0.001) while patient in poor health (CCS 4 to 6) had a nearly 4-fold greater odds of 
developing a VTE (versus CCS 0; OR: 3.73; p<0.001).  We also found that developing a 
symptomatic VTE was associated with minimally invasive surgery (versus open surgery; 
OR: 1.34; p<0.001), surgery at a teaching hospital (versus non-teaching; OR: 1.13; 
p=0.022) and surgery at an urban hospital (versus rural; OR: 1.40; p=0.003).    
 We found that health status was the strongest independent predictor for major 
bleeding associated with the radical prostatectomy (Table 3B.4).  Compared to healthy 
patients, those with a CCS between 7 and 10 had a 21-fold increased odds of major 
bleeding (versus CCS 0; OR: 21.00; p<0.001).  Major bleeding was also associated with 
advanced age and undergoing an open procedure (versus minimally invasive; OR: 1.33; 
p<0.001). 
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Use of Pharmacologic Thromboprophylaxis and Odds of Symptomatic VTE 
Among patients undergoing major urologic surgery, use of pharmacologic 
thromboprophylaxis was noted to decrease the odds of VTE only among patients 
undergoing radical prostatectomy surgery (OR: 0.55; p<0.001).  At the same time, there 
was a 24% increased odds of major bleeding (OR: 1.24; p<0.001).  In contrast, the use of 
pharmacologic thromboprophylaxis among patients undergoing radical nephrectomy was 
associated with an increased odds of developing a VTE (OR: 1.25; p<0.001) as well as a 
6% increased odds of major bleeding (OR: 1.06; p=0.03).  For partial nephrectomy and 
radical cystectomy surgery, the use of pharmacologic thromboprophylaxis was not 
significantly associated with an increase or decrease in the odds of developing a VTE or 
major bleeding.  
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Table 1. Baseline Characteristics of Patients by Major Urologic Surgery  
Total Patients (weighted)= 709,294 
 
 
Variable 
Partial 
Nephrectomy  
(n=58,035) 
Radical  
Nephrectomy 
(n=237,118) 
Radical 
Cystectomy 
(n=37,678) 
Radical 
Prostatectomy 
(n=376,462) 
Age 
Median (IQR) 
60 (17) 61 (22) 70(14) 62(10) 
Gender     
    Male 57.7%  54.8% 83.7% 100% 
    Female 42.3% 45.2% 16.3% N/A 
Pharmacologic 
Thromboprophylaxis  
9.47% 12.29% 19.08% 12.43% 
Charlson 
Comorbidity Score 
[Mean +/- SD] 
0.46+/-0.57 0.50+/-0.61 0.63+/-0.61 0.25+/-0.44 
Length of Stay (Days) 
Median(IQR) 
4(2) 4(3) 9(6) 2(2) 
Surgical Method     
    Open 70.6% 56.5% 86.6% 60.4% 
    Minimally Invasive 29.4% 43.5% 13.4% 39.6% 
Hospital Setting      
   Non-teaching 60.6% 71.1% 66% 70.6% 
   Teaching 39.4% 28.9% 34.0% 29.4% 
Hospital Location     
    Rural 3.4% 4.0% 3.6% 4.4% 
    Urban 96.6% 96.0% 96.4% 95.6% 
Table 2. Incidence of Clinical Events (weighted) 
Clinical Event Partial 
Nephrectomy 
Radical 
Nephrectomy 
Radical 
Cystectomy 
Radical 
Prostatectomy 
Venous 
Thromboembolism 
0.99%  
(n=572) 
1.52% 
(n=3, 603) 
5.33% 
(n=2,008) 
0.60% 
(n=2,274) 
Deep Venous 
Thrombosis 
0.59% 
(n=343) 
0.90% 
(n=2,138) 
3.74% 
(n=1,409) 
0.31% 
(n=1,181) 
Pulmonary 
Embolism 
0.54% 
(n=311) 
0.81% 
(n=1,923) 
2.54% 
(n=956) 
0.41% 
(n=1,531) 
Major Bleeding 4.18% 
(n=2,424) 
5.42% 
(n=12,851) 
8.24% 
(n=3,104) 
1.81% 
(n=6,801) 
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Table 3A. Partial Nephrectomy VTE Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 520 0.99% Reference  
   Yes 52 0.94% 0.86 0.30 
Length of Stay     
   Less than 2 Days 12 0.11% Reference  
   Greater than 2 Days 560 1.19% 13.84*** <0.001 
Charlson Comorbidity Score     
   0 292 0.88% Reference  
   1-3 258 1.14% 0.99 0.930 
   4-6 12 0.66% 0.47** 0.010 
   7-10 9 5.52% 3.47*** <0.001 
Age     
   Less than 40 9 0.21% Reference  
   40 to 49 64 0.73% 3.42*** <0.001 
   50 to 59 65 0.43% 2.08** 0.040 
   60 to 69 273 1.64% 7.72*** <0.001 
   70 to 79 148 1.37% 6.06*** <0.001 
   Greater than 80 13 0.6% 2.64** 0.030 
Gender     
   Male 398 1.19% Reference  
   Female 174 0.71% 0.66*** <0.001 
Surgery     
   Open 362 0.88%   
   Minimally Invasive 210 1.23% 1.82*** <0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 80 0.53% Reference  
      314 to 440 96 0.69% 1.28 0.100 
      440 to 623 211 1.41% 2.71*** <0.001 
      Greater than 623 185 1.31% 2.25*** <0.001 
   Type     
      Non-Teaching 287 0.82% Reference  
      Teaching 285 1.25% 1.300** 0.010 
   Location     
      Rural 17 0.86% Reference  
      Urban 555 0.99% 1.32 0.270 
Year   1.05 0.050 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 3B. Radical Nephrectomy VTE Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 3,035 1.46% Reference  
   Yes 568 1.95% 1.25** <0.001 
Length of Stay     
   Less than 2 Days 102 0.26% Reference  
   Greater than 2 Days 3,500 1.76% 5.02*** <0.001 
Charlson Comorbidity Score     
   0 1,339 1.03% Reference  
   1-3 1,854 1.96% 1.56*** <0.001 
   4-6 367 3.10% 2.17*** <0.001 
   7-10 42 4.36% 3.07*** <0.001 
Age     
   Less than 40 109 0.50% Reference  
   40 to 49 225 0.73% 1.28** 0.037 
   50 to 59 869 1.71% 2.71*** <0.001 
   60 to 69 860 1.44% 2.06*** <0.001 
   70 to 79 989 1.94% 2.63*** <0.001 
   Greater than 80 552 2.38% 3.17*** <0.001 
Gender     
   Male 2,233 1.72% Reference  
   Female 1,369 1.28% 0.78*** <0.001 
Surgery     
   Open 2,562 1.91% Reference  
   Minimally Invasive 1,041 1.01% 0.59*** <0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 1,047 1.53% Reference  
      314 to 440 1,058 1.56% 1.08* 0.084 
      440 to 623 709 1.38% 0.89** 0.026 
      Greater than 623 789 1.59% 1.20** <0.001 
   Type     
      Non-Teaching 2,505 1.49% Reference  
      Teaching 1,097 1.60% 1.10** 0.028 
   Location     
      Rural 162 1.72% Reference  
      Urban 3,440 1.51% 0.86* 0.075 
Year   1.02* 0.099 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 3C. Radical Cystectomy VTE Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 1,595 5.23% Reference  
   Yes 413 5.75% 1.04 0.503 
Length of Stay     
   Days   1.05*** <0.001 
Charlson Comorbidity Score     
   0 763 4.74% Reference  
   1-3 1,126 5.86% 1.08 0.117 
   4-6 105 4.61% 0.62*** <0.001 
   7-10 14 12.84% 2.25*** 0.005 
Age     
   Less than 40 4 1.71% Reference  
   40 to 49 36 2.47% 1.40 0.549 
   50 to 59 166 3.27% 2.14 0.158 
   60 to 69 598 5.33% 3.76** 0.013 
   70 to 79 900 6.42% 4.19*** 0.008 
   Greater than 80 305 5.35% 3.61** 0.017 
Gender     
   Male 1,708 5.42% Reference  
   Female 300 4.88% 0.89* 0.069 
Surgery     
   Open 1,679 5.14% Reference  
   Minimally Invasive 329 6.53% 1.23*** 0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 380 3.50% Reference  
      314 to 440 596 6.16% 1.70*** <0.001 
      440 to 623 444 5.23% 1.45*** <0.001 
      Greater than 623 588 6.79% 2.02*** <0.001 
   Type     
      Non-Teaching 1,280 5.15% Reference  
      Teaching 728 5.68% 0.909* 0.086 
   Location     
      Rural 86 6.41% Reference  
      Urban 1,922 5.29% 0.710*** 0.003 
Year   0.966** 0.015 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 3D.  Radical Prostatectomy VTE Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 2,098 0.64% Reference  
   Yes 176 0.38% 0.55** <0.001 
Length of Stay     
   Less than 2 Days 654 0.27% Reference  
   Greater than 2 Days 1,620 1.20% 4.83*** <0.001 
Charlson Comorbidity Score     
   0 1,622 0.57% Reference  
   1-3 606 0.66% 0.99 0.770 
   4-6 45 3.06% 3.73*** <0.001 
   7-10 0 0.00%   
Age     
   Less than 40 0 0.00%   
   40 to 49 81 0.43% Reference  
   50 to 59 727 0.57% 1.26 0.052 
   60 to 69 1,085 0.59% 1.27** 0.038 
   70 to 79 371 0.81% 1.63*** <0.001 
   Greater than 80 9 1.19% 1.75 0.109 
Surgery     
   Open 1,516 0.67% Reference  
   Minimally Invasive 758 0.51% 1.34*** <0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 656 0.62% Reference  
      314 to 440 605 0.54% 1.05 0.352 
      440 to 623 594 0.85% 1.35*** <0.001 
      Greater than 623 419 0.48% 1.03 0.642 
   Type     
      Non-Teaching 1,622 0.61% Reference  
      Teaching 651 0.59% 1.13** 0.023 
   Location     
      Rural 89 0.54% Reference  
      Urban 2,185 0.61% 1.38*** 0.003 
Year   0.96*** 0.003 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 4A. Partial Nephrectomy Major Bleeding Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 2,194 4.18% Reference  
   Yes 230 4.19% 0.919 0.245 
Charlson Comorbidity Score     
   0 1,140 3.42% Reference  
   1-3 1,110 4.89% 1.349*** <0.001 
   4-6 137 7.32% 1.859*** <0.001 
   7-10 37 21.57% 5.365*** <0.001 
Age     
   Less than 40 141 3.25% Reference  
   40 to 49 378 4.31% 1.282** 0.014 
   50 to 59 483 3.17% 0.867 0.144 
   60 to 69 571 3.44% 0.897 0.263 
   70 to 79 748 6.90% 1.872*** <0.001 
   Greater than 80 103 4.64% 1.222 0.135 
Gender     
   Male 1,538 4.59% Reference  
   Female 886 3.61% 0.818*** <0.001 
Surgery     
   Open 1,721 4.20% Reference  
   Minimally Invasive 703 4.12% 0.961 0.394 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 560 3.73% Reference  
      314 to 440 620 4.45% 1.228*** 0.001 
      440 to 623 710 4.75% 1.224*** 0.001 
      Greater than 623 534 3.77% 0.907 0.151 
   Type     
      Non-Teaching 1,394 3.96% Reference  
      Teaching 1,030 4.51% 1.202*** <0.001 
   Location     
      Rural 63 3.20% Reference  
      Urban 2,361 4.21% 1.260* 0.079 
Year   1.205*** <0.001 
OR=Odds Ratio 
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 4B. Radical Nephrectomy Major Bleeding Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 11,112 5.34% Reference  
   Yes 1,739 5.97% 1.0601** 0.0322 
Charlson Comorbidity Score     
   0 5,548 4.27% Reference  
   1-3 6,001 6.35% 1.3373*** <0.001 
   4-6 1,124 9.49% 1.8164*** <0.001 
   7-10 178 18.53% 4.0971*** <0.001 
Age     
   Less than 40 582 2.68% Reference  
   40 to 49 1,220 3.94% 1.3768*** <0.001 
   50 to 59 2,905 5.73% 1.8742*** <0.001 
   60 to 69 3,192 5.36% 1.6480*** <0.001 
   70 to 79 3,224 6.33% 1.9557*** <0.001 
   Greater than 80 1,729 7.45% 2.3303*** <0.001 
Gender     
   Male 7,777 5.98% Reference  
   Female 5,074 4.73% 0.8117*** <0.001 
Surgery     
   Open 8,329 6.22% Reference  
   Minimally Invasive 4,523 4.38% 0.7053*** <0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 3,621 5.30% Reference  
      314 to 440 3,904 5.74% 1.1503*** <0.001 
      440 to 623 3,117 6.09% 1.1668*** <0.001 
      Greater than 623 2,210 4.46% 0.9177*** 0.0051 
   Type     
      Non-Teaching 9,205 5.46% Reference  
      Teaching 3,646 5.33% 1.0149 0.5239 
   Location     
      Rural 554 5.89% Reference  
      Urban 12,297 5.40% 0.8713*** 0.0024 
Year   1.1908*** <0.001 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 4C. Radical Cystectomy Major Bleeding Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 2,484 8.15% Reference  
   Yes 619 8.62% 1.0463 0.3492 
Charlson Comorbidity Score     
   0 958 5.96% Reference  
   1-3 1,730 9.01% 1.5029*** <0.001 
   4-6 398 17.49% 3.0081*** <0.001 
   7-10 18 16.12% 2.8053*** 0.0001 
Age     
   Less than 40 16 7.55% Reference  
   40 to 49 93 6.39% 0.7630 0.3413 
   50 to 59 293 5.78% 0.6575 0.1200 
   60 to 69 769 6.85% 0.7453 0.2683 
   70 to 79 1,310 9.34% 0.9658 0.8955 
   Greater than 80 623 10.94% 1.1916 0.5106 
Gender     
   Male 2,598 8.24% Reference  
   Female 506 8.23% 1.0302 0.5627 
Surgery     
   Open 2,634 8.07% Reference  
   Minimally Invasive 470 9.34% 1.0402 0.4662 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 670 6.16% Reference  
      314 to 440 952 9.84% 1.7203*** <0.001 
      440 to 623 773 9.12% 1.6679*** <0.001 
      Greater than 623 709 8.20% 1.5028*** <0.001 
   Type     
      Non-Teaching 2,082 8.37% Reference  
      Teaching 1,022 7.97% 0.8785*** 0.0045 
   Location     
      Rural 93 6.89% Reference  
      Urban 3,011 8.29% 1.0964 0.4079 
Year   1.1856*** <0.001 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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Table 4D. Radical Prostatectomy Major Bleeding Incidence and Logistic Regression Analysis 
 Incidence Multivariate 
 No. % OR P-Value 
Pharmacologic Thromboprophylaxis     
   No 5,814 1.76% Reference  
   Yes 988 2.11% 1.2436*** <0.001 
Charlson Comorbidity Score     
   0 4,450 1.57% Reference  
   1-3 2,257 2.47% 1.4951*** <0.001 
   4-6 86 5.79% 3.3827*** <0.001 
   7-10 8 24.31% 20.9819*** <0.001 
Age     
   Less than 40 0 0.00% N/A  
   40 to 49 213 1.14% Reference  
   50 to 59 1,898 1.49% 1.2401*** 0.0031 
   60 to 69 3,630 1.98% 1.6017*** <0.001 
   70 to 79 1,001 2.18% 1.7063*** <0.001 
   Greater than 80 60 7.63% 5.8080*** <0.001 
Surgery     
   Open 4,573 2.01% Reference  
   Minimally Invasive 2,229 1.49% 0.7498*** <0.001 
Hospital Characteristics     
   Size (Number of Beds)     
      Less than 314 2,163 2.04% Reference  
      314 to 440 2,120 1.89% 0.9828 0.5826 
      440 to 623 1,320 1.89% 0.9686 0.3956 
      Greater than 623 1,198 1.37% 0.7491*** <0.001 
   Type     
      Non-Teaching 5,053 1.90% Reference  
      Teaching 1,748 1.58% 0.9435* 0.0636 
   Location     
      Rural 304 1.83% Reference  
      Urban 6,497 1.81% 1.0786 0.2060 
Year   1.0459*** <0.001 
OR=Odds Ratio  
Asterisks denote level of significance: ***: p<0.001 | **: p<0.05 | *: p<0.10 
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DISCUSSION 
 
Incidence of Symptomatic Venous Thromboembolisms and Major Bleeding Episodes in 
Urologic Surgery 
Our contemporary analysis of a nationally representative cohort found that the occurrence 
of VTE and major bleeding is relatively low.  By major urologic surgery, we found the 
rates of symptomatic VTE to be 0.99% in partial nephrectomies, 1.52% in radical 
nephrectomies, 5.33% in radical cystectomies, and 0.60% in in radical prostatectomies 
over our six-year study period. Furthermore, we found that the rates of major bleeding in 
major urologic surgery were 4.18% in partial nephrectomies, 5.42% in radical 
nephrectomies, 8.24% in radical cystectomies, and 1.81% in radical prostatectomies.  
Additionally, we failed to demonstrate a clinically significant reduction in post-operative 
symptomatic VTE with the use of pharmacologic thromboprophylaxis among patients 
undergoing major urologic surgery. 
 
 
Radical Prostatectomy 
Contemporary studies have reported rates of symptomatic VTE in the range of 0.50% to 
2.0%10-14.  A majority of these studies have focused on the open radical retropubic 
prostatectomy with or without pharmacologic thromboprophylaxis.  Interestingly, Secin 
et al.12 only examined patients undergoing laparoscopic and robot-assisted laparoscopic 
radical prostatectomy with and without pharmacologic thromboprophylaxis and reported 
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rates of 0.50%.  Our number of 0.60% falls within the previously reported range of 
numbers, but our study improves on previous estimates because it was much larger in 
scope and was not subject to biases like low power, single-institution studies or physician 
practices. 
 The AUA best practice guidelines for DVT prevention suggest that patients 
undergoing radical prostatectomy study are at high risk for VTE, although neither the 
current study nor other contemporary studies have found this risk to be high.  A number 
of possible reasons may explain why patients undergoing radical prostatectomy surgery 
have a relatively low incidence of thromboembolic events.  It is well established that 
patients undergoing radical prostatectomy surgery tend to have shorter operating times, 
low rates of intraoperative blood loss,  fewer complication, fewer comorbidities and 
higher surgical volume relative to other major urologic surgeries11,14-16. Also, patients 
undergoing radical prostatectomy surgery have short hospital stays and are quick to begin 
ambulation after surgery.  While cancer has been implicated as a risk factor for 
developing a VTE17,18 by promoting a hypercoagulable state through procoagulant and 
fibrinolytic factors, inflammatory processes, necrosis, and activation of host cells, 
individual cancers carry different risk profiles, prostate cancer has one of the lowest risks, 
among all cancers, for developing a VTE17.  The fact that patients undergoing a radical 
prostatectomy have a relatively lower risk of developing a VTE compared to other 
patients undergoing major urologic procedures, suggests the need for a more nuanced 
approach to risk stratification and pharmacologic thromboprophylaxis. 
Patients who were at highest risk for developing a VTE in our study were those 
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who stayed longer than two days in the hospital, had advanced comorbidity, were older 
and underwent a minimally invasive procedure.  Others have reported similar findings 
that increased hospital time, age and high comorbidity contribute to increased rates of 
VTE10. For example, Scarpa et al.10 found that greater than four days stay in the hospital, 
age greater than 60 and operating times longer than two hours were significant risk 
factors for developing a VTE, while Secin et al.12 found that length of stay and longer 
operating times were associated with higher rates of VTE in patients undergoing 
minimally invasive radical prostatectomies.  We also found that patients undergoing 
surgery at teaching hospitals were at higher risk for undergoing a VTE.  Reasons for this 
may include the fact that teaching hospitals have a tendency to see more surgically 
complex patients, with more advanced disease and thus contribute to the increased risk of 
VTE. 
 Patients who underwent a minimally invasive procedure may have a higher risk of 
developing a VTE due to high pressure CO2 insufflation of the abdomen and a negative 
Trendelenburg position, thus reducing venous flow and promoting thrombosis 
formation19.  Minimally invasive techniques may also increase the rate of VTE because 
shorter hospital stays may cause patients to stop receiving prophylaxis after they leave 
the hospital, even though the risk of having an event remains elevated for six weeks and 
long after they have returned home20.  As minimally invasive procedures are being 
increasingly used in radical prostatectomy surgery, the question of the relative risk of this 
procedure and appropriate prophylaxis guidelines for these patients warrants further 
investigation. 
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 We found the use of pharmacologic thromboprophylaxis to be associated with a 
lower risk of developing a VTE, but at the expense of an increased risk of major 
bleeding.  Other studies have similarly demonstrated that the administration of heparin 
reduces the number of thromboembolic events in radical prostatectomy surgery, but that 
heparin may increase the number of bleeding events and contributes to intraoperative 
blood loss21. Catalonia et al.14 estimated intraoperative blood loss to be greater in those 
patients receiving heparin perioperatively and Scarpa et al.10 found that patients receiving 
pharmacologic thromboprophylaxis had a 244% greater odds of bleeding during surgery 
although they did not distinguish between different urologic surgeries.  Secin et al.12 also 
found that patients who received prophylaxis heparin preoperatively had greater amounts 
of intraoperative blood loss, higher rates of transfusion and longer hospital stays.  
Montgomery et al. found that for patients undergoing urologic laparoscopic surgery, use 
of unfractionated heparin was associated with an increase in hemorrhagic 
complications22.  
 
Radical Cystectomy 
The reported rates of VTE in radical cystectomy surgery stand in sharp contrast to those 
reported in radical prostatectomy surgery.  Comparing rates of VTE across a wide range 
of surgeries from the California Patient Discharge Dataset, White et al. found a 
postoperative VTE rate of 3.7% for the radical cystectomy, the highest of all surgeries 
considered23.  Clement et al. reported a symptomatic VTE rate of 5.8% and an overall 
VTE rate of 24% in a review of 86 patients, despite all patients receiving pharmacologic 
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prophylaxis24.  Shabsigh et al found a symptomatic VTE rate of 8% from a series of 1,142 
patients25. Rosario et al. examined 101 patients undergoing radical cystectomy surgery 
and found a symptomatic VTE rate of 5.9%26.  Our estimate of 5.33% for the rate of 
symptomatic VTE in radical cystectomy surgery is consistent with previously published 
results and supports the notion that the risk of developing a VTE is much higher in 
patients undergoing radical cystectomy compared to other types of major urologic 
surgery, especially radical prostatectomy surgery. 
 The high incidence of VTE in patients undergoing radical cystectomy surgery is 
likely due to the fact that the procedure is predominately performed on an elderly 
comorbid patient population, with high rates of cardiac and vascular comorbidities, high 
rates of re-exploration, high rates of transfusion, smoking history, obesity, extensive 
pelvic dissection, use of adjuvant and neoadjuvant chemotherapy, central venous 
catheterization, cancer-specific VTE risk profiles and prolonged hospital stays8.  All of 
these factors have been implicated in putting patients at a very high risk for developing a 
VTE4,10,27. Indeed, in our study cohort, patients undergoing radical cystectomy surgery 
were by far the oldest with a median age of 70 years, had the highest average CCS out of 
all patients considered and spent the longest time in the hospital.  Studies examining the 
patient population and complication rates of those undergoing radical cystectomy surgery 
confirm our findings24,26.  For example, from a comprehensive single institution review of 
1,142 patients undergoing radical cystectomy surgery, Shabsigh et al. reported an overall 
complication rate of 64%, a median surgical time of 6.4 hrs, 66% of patients required 
perioperative blood product transfusions, 16% of the patients had previously undergone 
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either chemo- or radio-therapy, 30% of patients had a CCS greater than two, and 94% of 
the patients were obese25.   
 In our study we were able to confirm that advanced age, length of hospital stay, 
and the severity of a patient’s comorbidities increased the risk of developing a VTE.  The 
severity of a patient’s comorbidities may increase the risk of developing a VTE by 
increasing the length of operating time, length of hospital stay and consequent stasis, or 
may be associated with cardiopulmonary pathologies which may reduce venous blood 
flow and promote formation of thromboemboli.  Interestingly, we noted that patients 
undergoing minimally invasive radical cystectomy had a higher incidence of VTE. This 
may be explained by the fact that this is a relatively new procedure and requires a steep 
learning curve and at least initially may require longer operating times and may be 
associated with more complications28.  Also, it has been noted that some of the most 
difficult cases are performed using robotic techniques, especially those on the morbidly 
obese and therefore may explain the increased risk of VTE29.  As previously mentioned, 
minimally invasive techniques may also increase the risk of VTE by increasing 
abdominal pressure, differences in patient positioning compared to open, and shortened 
prophylaxis regimens due to reduced hospital stays.  In one of the largest comparative 
series on complications between open and robotic radical cystectomy, Ng et al. also 
reported that patients undergoing robotic radical cystectomy had higher rates of VTE than 
those undergoing open surgery30. 
 We did not find a statistically significant difference in the rate of VTE between 
those patients who received pharmacologic thromboprophylaxis and those who did not.  
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To our knowledge there have been no publications examining the efficacy of 
pharmacologic prophylaxis in patients undergoing radical cystectomy surgery.  As 
previously described, patients undergoing radical cystectomy surgery are at extremely 
high risk for developing VTE.  Even when patients received pharmacologic prophylaxis 
for up to 15 days after surgery, Clement et al. reported high rates of symptomatic VTE 
and other have reported that despite the use of rigorous prophylactic measures, high rates 
of VTE were noted31.  It may be entirely possible, given how at-risk this population is, 
that current protocols for VTE prophylaxis are entirely insufficient.  For example, Agnelli 
et al. report that 40% of patients undergoing cancer surgery developed a symptomatic 
VTE 21 days after surgery, a period of time after which VTE prophylaxis would have 
been stopped32.  There is evidence to suggest that prolonged prophylaxis may reduce the 
risk of VTE in patients undergoing radical cystectomy surgery.  For example, Phillips et 
al. report that since adopting a comprehensive VTE prophylaxis protocol in which a 
patient receives LMWH for 42 days after surgery, there has only been one case of 
nonfatal pulmonary embolism33.  Furthermore, in a prospective, randomized controlled 
trial Bergqvist et al. found that patients undergoing cancer surgery who received 
prophylaxis up to one month after surgery had a 60% reduction in the risk of developing 
a VTE compared to the control group which only received prophylaxis up to 10 days 
after surgery34.  Other studies have also noted that prolonged (28-45 days) pharmacologic 
thromboprophylaxis in pelvic surgery reduces the risk of VTE compared to prophylaxis 
regimes of shorter duration35,36.  Our research underscores the need for further 
investigation into the appropriate use of pharmacologic thromboprophylaxis in patients 
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undergoing radical cystectomy surgery.  
 
Nephrectomy Surgery 
Very little literature exists on the rate of VTE in patients undergoing partial or radical 
nephrectomy surgery.  Recently, Pettus et al. reported an overall rate of 1.5% for 
symptomatic VTE in a retrospective review of 2,208 patients who underwent any type of 
partial or radical nephrectomy7.  Interestingly, the only thromboprophylaxis utilized in 
these cases was pneumatic compression boots.  In a retrospective examination the 
California Patient Discharge Data Set, White et al. reported a symptomatic VTE rate of 
2.0% in patients with malignancy and 0.4% in non-cancer patients undergoing radical 
nephrectomy surgery23.  Our findings of a rate of 1.5% for VTE in radical nephrectomy 
surgery and a rate of 0.99% for VTE in partial nephrectomy surgery is consistent with 
existing literature.  Our rate of 1.5% for patients undergoing radical nephrectomy surgery 
may underestimate the incidence of those patients who undergo the surgery for malignant 
tumors, as we did not distinguish between those patients who underwent the procedure 
for malignant versus benign tumors, as renal cell carcinoma has been reported to carry an 
increased VTE risk17,37.  Patients undergoing partial nephrectomy may have a decreased 
VTE risk due to the fact that they are healthier and have fewer comorbidities compared to 
patients undergoing radical nephrectomy surgery and are considered to have localized 
disease rather than overtly malignant carcinoma.  Furthermore, patients undergoing 
radical nephrectomy may also have increased rates of VTE due to the fact that locally 
advanced renal disease may cause reduced venous flow by the presence of a tumor in the 
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renal vein or vena cava, and/or the tumor may mechanically compress the vena cava7. 
 Our study shows that length of hospital stay, sicker patients, advanced age and 
having the surgery performed at a teaching hospital were all associated with the 
development of symptomatic VTE.  Length of hospital stay is likely associated with 
prolonged immobility, later ambulation and surgical complication, all factors that 
increase the risk of VTE4.  Both comorbidities and advanced age have also been 
demonstrated to increase the risk of VTE4.  Teaching hospital may see more advanced 
disease and as a result require more surgically complex procedures with higher rates of 
complications and may increase the length of operating room time, all factors that 
increase the risk of VTE.   We noted that women were less likely to have a VTE and this 
may be due to the fact that women are generally more healthy or may have an inherently 
lower risk of developing a VTE.   
 Patients undergoing minimally invasive partial nephrectomy surgery had higher 
rates of VTE, while patients undergoing minimally invasive radical nephrectomy surgery 
had lower rates of VTE.  This apparent contradiction may be explained by the fact that 
minimally invasive partial nephrectomy surgery is considered a technically challenging 
procedure requiring longer operative times, and also commonly associated with an period 
of bed-rest immediately following surgery, which may increase the risk of VTE.  
Minimally invasive radical nephrectomy surgery is more established and less technically 
demanding and consequently it is likely that shorter hospital stays and earlier ambulation 
compared to patients undergoing open surgery may result in a decreased risk of VTE.  
 We observed that patients undergoing radical nephrectomy surgery had a higher 
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risk of developing a VTE if they received pharmacologic prophylaxis.  While no studies 
have been conducted demonstrating the efficacy of pharmacologic thromboprophylaxis in 
nephrectomy surgery, others have reported a similar finding in radical prostatectomy 
surgery12.  In our adjusted model, we observed that the use of pharmacologic 
thromboprophylaxis increased the rate of bleeding in radical nephrectomy surgery and 
others have noted that pharmacologic prophylaxis use in urologic surgery increased the 
rate of blood loss10, increased transfusion rates and led to longer hospital stays12.  Large 
volumes of blood loss and transfusion of blood products have been implicated in an 
increased risk of developing a VTE38,39.  Increased rates of bleeding and pharmacologic 
thromboprophylaxis use have been associated with the formation of lymphocele and 
hematomas21,40 and may increase the risk of developing a VTE after surgery by 
compressing or occluding the vena cava or iliac veins13.  Because nephrectomy surgery 
differs from other major urologic surgery in its close proximity to highly vascular 
structures and that the patient population appears to be relatively low risk for developing 
a VTE, it is possible that the higher rates of bleeding due to pharmacologic prophylaxis 
may actual increase the risk of developing a VTE.  
 
Major Bleeding Episodes in Major Urologic Surgery 
Only in radical nephrectomy surgery and prostatectomy surgery did we find the use of 
pharmacologic prophylaxis to be associated with increased rates of major bleeding.  In all 
others, the rates of major bleeding episodes were comparable to those patients who did 
not receive pharmacologic thromboprophylaxis.  Studies have reported conflicting results 
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as to whether the use of pharmacologic thromboprophylaxis increases the rate of major 
bleeding in urologic and cancer surgery.  For example, there have been numerous large 
scale studies suggesting that the use of perioperative pharmacologic thromboprophylaxis 
increases the rate of minor bleeding in pelvic surgery, but when rates of major bleeding 
or fatal bleeding are considered these studies failed to demonstrate a link between 
injectable anticoagulation use and major bleeding41-43.  In a smaller study done in urologic 
procedures Scarpa et al. found an increased rate of bleeding in those patients who 
underwent urologic procedures and received pharmacologic thromboprophylaxis, but 
when major bleeding episodes were considered the surgeons did not attribute the major 
bleeding to pharmacologic prophylaxis use10.  Others, though, have reported that 
pharmacologic prophylaxis use may increase the rate of major bleeding in urologic 
surgery.  Secin et al.12 reported that pharmacologic prophylaxis use in radical 
prostatectomy surgery was associated with an increased intraoperative blood loss and 
transfusion rate and Bigg et al.21 in a prospective trial of pharmacologic 
thromboprophylaxis in radical prostatectomy surgery reported that intraoperative blood 
loss and transfusion rates were higher in those patients who received anticoagulation21, 
although the results were not significantly significant most likely due to small sample 
size.   
Because the effect of pharmacologic prophylaxis use on major bleeding appears 
to be small at best, we are not surprised to see that pharmacologic prophylaxis use is not 
uniformly associated with increased rates of major bleeding episodes.  Rather than a true 
absence of a bleeding risk with thromboprophylaxis, it is feasible that the sample size for 
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the partial nephrectomy and radical cystectomy cohorts was of insufficient size to achieve 
a statistically significant result.  Importantly, the current study did not study the potential 
effect of pharmacologic thromboprophylaxis on hematoma and lymphocele formation.  In 
some studies it has been shown that anticoagulation therapy increases the rate of 
formation of these events and that they represent a potential complication with the use of 
these drugs and may be a potential risk factor in developing a VTE13.  We did not 
examine whether the duration of use of pharmacologic thromboprophylaxis increases the 
rate of major bleeding, but in robust, prospective trials, prolonged anticoagulation use did 
not appear to increase the risk of bleeding34-36, although none of these studies explicitly 
examined prolonged anticoagulation use in urologic procedures.  
 We examined independent risk factors associated with major bleeding in urologic 
procedures.  Almost uniformly, advanced age, comorbidity severity and having the 
procedure performed at a teaching hospital were associated with increased rates of major 
bleeding episodes.  These patients may have an inherently higher risk of bleeding or may 
represent more difficult cases and therefore are more likely to have a major bleeding 
episode during a urologic procedure.  Patients undergoing major urologic surgery at a 
teaching hospital may be at increased risk of bleeding because physicians at teaching 
hospitals are more likely to administer pharmacologic prophylaxis or that they represent 
more surgically challenging cases.  In both radical and partial nephrectomy women were 
at a lower odds of developing a major bleeding episode and this may be due to the fact 
that they represent a healthier patient population associated with few complications 
during urologic surgery.  In radical cystectomy surgery, there was no difference in rates 
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of major bleeding between genders; the radical cystectomy surgery is generally 
considered to be a more technically challenging procedure in women and therefore the 
benefit of being a women with respect to a reduced odds of major bleeding in urologic 
surgery may abrogated by the more complex surgical procedure.  There was a lower risk 
of major bleeding in patients undergoing minimally invasive surgery in radical 
prostatectomy and nephrectomy surgery, but none observed in the partial nephrectomy 
and radical cystectomy group.  Minimally invasive procedures for radical prostatectomy 
and radical nephrectomy surgery are well established and higher surgical case volume in 
these procedures may have given surgeons time to perfect their technique.  In contrast, 
minimally invasive procedures for partial nephrectomy and radical cystectomy are both 
considered more technically challenging procedures that may require a longer period to 
achieve proficiency.  This fact underscores the point that surgeons learning new 
minimally invasive techniques should begin with patients who are relatively younger and 
with fewer comorbidities, before applying these methods to other patient populations.  In 
considering the administration of pharmacologic prophylaxis to patients undergoing 
major urologic surgery, it may be wise to chose alternative methods of prophylaxis like 
sequential compression devices, graduated compression stockings, early ambulation, 
and/or delayed administration of anticoagulation to patient populations who are at 
particularly high risk for major bleeding episodes during urologic procedures.  
 
Association of VTE with Pharmacologic Thromboprophylaxis 
Besides the surgery specific reasons we outlined above, we may not have observed a 
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strong association between pharmacologic thromboprophylaxis use and the incidence of 
VTE for a number of reasons.  First, we may not have been able to capture all the patients 
who actually received injectable anticoagulation because some surgeons may have 
administered it on the day after surgery.  We note, at least in the case of radical 
cystectomy surgery, that some surgeons prefer to administer the pharmacologic 
prophylaxis postoperatively day one29.  Patients who received pharmacologic 
anticoagulation in this manner would have been counted in our study as not receiving it at 
all, yet by receiving it would have decreased the incidence of VTE in the group that was 
counted as not having received it.  We did not count patients receiving pharmacologic 
thromboprophylaxis in this manner as the general appropriateness of such a 
pharmacologic prophylaxis regimen remains questionable except in those patients at very 
high risk of bleeding4.  Administration of pharmacologic prophylaxis on the day of 
surgery is considered best practice as it is hypothesized that thrombosis formation occurs 
during surgery as a consequence of anesthesia, prolonged stasis and vascular trauma4.  
Nonetheless, this may have lowered the incidence of VTE in the group we categorized as 
not receiving pharmacologic thromboprophylaxis.  
Second, we did not account for the duration of administration of the 
pharmacologic thromboprophylaxis.  There have been reports within the urologic 
community33 and high-level, prospective studies in patients undergoing pelvic surgery34 
that extended duration of pharmacologic thromboprophylaxis may lead to lower rates of 
VTE than those simply administered for the duration of a patient’s hospital stay, as the 
risk of developing a VTE remains high for four to six weeks after surgery.  Accounting 
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for the duration of prophylaxis is essential in determining the efficacy of pharmacologic 
therapy and is not a trivial matter as only extended prophylaxis may actually reduce the 
rate of VTE.  As previously mentioned, studies have reported high rates of VTE in 
patients undergoing radical cystectomy surgery despite a strict 15 day prophylaxis 
regimen24, while others using an extended prophylaxis regimen for up to 42 days have 
experienced much lower rates of VTE33.  By not knowing the duration of prophylaxis, we 
could not account for the effect that duration may have had on the outcome of VTE in 
urologic surgery.  If a patient received pharmacologic prophylaxis on the day of surgery, 
while another patient received it for an extended period of time, they would both have 
been counted in the group as having received it, but the effect pharmacologic prophylaxis 
would have had on reducing the incidence would have been different.  For example, the 
patient who only received pharmacologic prophylaxis on the day of surgery may not have 
had any reduction in the odds of developing a VTE and therefore would have diluted the 
observed effect that pharmacologic prophylaxis had on reducing the overall incidence of 
VTE in our patient population. 
Lastly, there may be an issue with selection bias.  Surgeons may only administer 
these drugs to patients who are perceived to be at particularly high risk for developing a 
VTE.  While pharmacologic prophylaxis has been shown to reduce the risk of developing 
a VTE, there is still a chance that despite utilization of the pharmacologic prophylaxis, 
especially in high risk patients, that there is still a significant risk of developing a VTE 
and that prophylaxis may only prevent nonfatal VTE from forming.  Thus by only 
administering the pharmacologic thromboprophylaxis to a very high risk population, the 
 37 
overall reduction in the incidence of these events may be lower than what we would 
observe if the drugs were administered to the general surgical population as a whole.  
 
Limitations 
Our analysis has potential limitations.  We used billing codes to determine if a patient 
received pharmacologic thromboprophylaxis and to see if they underwent minimally 
invasive urologic surgery.  Despite exhaustive efforts to capture all patients who 
received anticoagulation and those who underwent minimally invasive surgery, we 
cannot exclude the fact that we did not capture a small number of patients who received 
these, but were not counted as such.  By using a large study cohort, we hoped to 
ameliorate any potential bias that this may have injected into our study.  Our analysis did 
not include potentially important predictors of developing a VTE, like length of 
operating time, transfusion of blood during surgery, number of prior hospitalizations and 
a history of VTE.  We also made the assumption that all patients undergoing major 
urologic surgery received mechanical thromboprophylaxis in the form of sequential 
compression devices, although we did not explicitly verify this.  We did not have 
information on the staging of each patients disease and this may have affected the 
incidence of developing a VTE.  This is especially important in patients who had radical 
nephrectomy surgery as advanced renal carcinoma can extend into the renal vein and 
vena cava, putting the patient at especially high risk of developing a VTE. This study 
may be improved by using propensity score matching techniques to assess the efficacy 
of pharmacologic thromboprophylaxis in preventing VTE.  Also, we were not able to 
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examine surgeon practices or attitudes towards pharmacologic prophylaxis use, nor were 
we able to capture the duration of anticoagulation, which may have had an important 
effect of the outcome of VTE in this patient population.  
 
Conclusion 
Overall, we found the incidence of symptomatic VTE to be low in the major 
urologic surgeries we considered.  Our study and the existing body of literature suggests 
that urologic surgery carries a unique VTE risk profile from other major pelvic surgeries10 
and furthermore that there are different risk profiles associated with different urologic 
surgeries8.  We did not observe a significant reduction in the rate of VTE with 
pharmacologic thromboprophylaxis in most surgeries considered, except for the radical 
prostatectomy and in that case it was noted to be low, with an additional cost of increased 
major bleeding episodes.  Our contemporary study calls into question, when if at all, it is 
appropriate to use pharmacologic thromboprophylaxis in major urologic surgery, except 
in those patients who are at particularly high risk or who are undergoing a high risk 
procedure, like the radical cystectomy.  Our research underscores the need for further 
research in the form of high-level studies and cost-effectiveness analyses to elucidate the 
role of pharmacologic thromboprophylaxis in urologic surgery.  
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